Disclaimer: This site aggregates publicly available data from official government sources (FDA, ClinicalTrials.gov, PubMed, SEC EDGAR) for general reference only. It does NOT constitute medical advice, diagnosis, treatment recommendations, or investment advice.

Clinical Trial

Phase 1/2a Study of ANPD001 in Parkinson Disease

NCT: NCT06344026 · ENROLLING_BY_INVITATION

NCT IDNCT06344026
StatusENROLLING_BY_INVITATION
Start Date2024-01-23
Completion2030-04-30
SponsorAspen Neuroscience (INDUSTRY)
First posted
Last updated

Brief Summary

This clinical trial is designed to test the safety and tolerability of injecting ANPD001 cells that will mature into dopamine-producing cells into the brain of participants with Parkinson Disease. All participants will have ANPD001 cells manufactured from their own previously collected cells.

Official Source

View on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov API. For the most current status, refer to the official record.

↑